Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Non-Small-Cell Lung Cancer|Breast Cancer
Interventions: DRUG: Vinorelbine oral
Sponsor: Pierre Fabre Pharma GmbH
Collaborators: Winicker Norimed GmbH